Sort
326,823 grants matching “clinical trial”
Children's Oncology Group Phase 1 / Pilot Consortium
$2,483,710Susan M Blaney · National Childhood Cancer Foundation · U01 · FY2008 · CA
INSTITUTIONAL CTSA (UW-MADISON): CLINICAL TRIALS
$2,483,644Marc K. Drezner · University Of Wisconsin-Madison · UL1 · FY2007 · RR
CANOE Partnership: Cancer Awareness, Navigation, Outreach, and Equitable Indigenous Health Outcomes
$2,483,619Lonnie A. Nelson · Fred Hutchinson Cancer Center · U19 · FY2024 · MD
THE THERAPY OF AML
$2,483,417Michael W Andreeff · University Of Tx Md Anderson Can Ctr · P01 · FY2010 · CA
Dana Farber/Harvard Cancer Center Ovarian Cancer SPORE grant
$2,483,069Alan David D'andrea · Dana-Farber Cancer Inst · P50 · FY2020 · CA
Coordinating Center for CALERIE
$2,482,842James Rochon · Duke University · U01 · FY2006 · AG
Metabolic Bone Disorders Unit
$2,482,792Alison Boyce · National Institute Of Dental & Craniofacial Research · ZIA · FY2024 · DE
Pulmonary innate immune activation for bioterror defense
$2,482,689Coley Pharmaceutical Group, Inc. · U01 · FY2004 · AI
Dana-Farber/Harvard Cancer Center SPORE in Breast Cancer
$2,482,574Eric P Winer · Dana-Farber Cancer Inst · P50 · FY2019 · CA
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
$2,482,205Jan Johansson · Artery Therapeutics, Inc. · R44 · FY2023 · AG
PDX Trial Center for Breast Cancer Therapy
$2,482,191Alana L Welm · University Of Utah · U54 · FY2017 · CA
Studies of Ocular inflammation: Clinical & Translational Research
$2,482,189Shilpa Kodati · National Eye Institute · ZIA · FY2021 · EY
SPORE in Lymphoma
$2,482,109Johns Hopkins University · P50 · FY2003 · CA
Core C: Biosecurity Core
$2,481,967James W. Leduc · University Of Texas Med Br Galveston · UC7 · FY2023 · AI
NHLBI SCIENTIFIC REVIEW AND SCIENTIFIC PORTFOLIO ANALYSIS (SR/SPA) SOLUTION AND SUPPORT SERVICES WITH ARPA-H SUPPORT (SR/SPA) SERVICES
$2,481,890Laurie Lucas · Four Points Technology, Llc · N02 · FY2024 · HL
Development of a Soluble Epoxide Hydrolase Inhibitor to Spare or Replace Opioid Analgesics
$2,481,856Irene Cortes-Puch · Eicosis, Llc · UH3 · FY2025 · DA
Defining the pathogenic relationship of TDP-43 inclusions and cytoplasmic double stranded RNA in AD and FTD
$2,481,834Mark W Albers · Harvard Medical School · RF1 · FY2022 · AG
Acylovir to prevent HIV acquisition in HSV-2+persons
$2,481,754University Of Washington · R01 · FY2003 · AI
(EET Biobank) NCI Early-Phase and Experimental Clinical Trials Biospecimen Bank
$2,481,702Kathleen Nicol · Research Inst Nationwide Children'S Hosp · U24 · FY2022 · CA
CD11b: A Novel Alternate Receptor for CD154 during Alloimmunity
$2,481,496Mandy L. Ford · Emory University · R01 · FY2025 · AI
Biodefense and Emerging Infectious Disease Monoclonal Antibody Studies
$2,481,382Julie E. Ledgerwood · National Institute Of Allergy And Infectious Diseases · ZIA · FY2019 · AI
Center for the Study of Aphasia Recovery (C-STAR)
$2,480,690Julius Fridriksson · University Of South Carolina At Columbia · P50 · FY2022 · DC
University of Puerto Rico Clinical Trials Unit
$2,480,642Carmen D Zorrilla · University Of Puerto Rico Med Sciences · U01 · FY2009 · AI
Tailored Retention and Engagement for Equitable Treatment of OUD and Pain (TREETOP)
$2,480,623Jessica S Merlin · University Of Pittsburgh At Pittsburgh · RM1 · FY2024 · DA
Continuation of the Chronic Renal Insufficiency Cohort (CRIC) Study
$2,480,000Harold I Feldman · University Of Pennsylvania · U01 · FY2015 · DK